Cipla’s US Unit Recalls Lanreotide Injection, Temporary Supply Shortage Expected

Pharmaceutical major Cipla has confirmed that its US unit will initiate a recall of Lanreotide injection. The move comes amid regulatory scrutiny and is expected to temporarily disrupt supply chains, affecting patients dependent on the medication.  

Reason For Recall  
The recall is linked to quality and compliance concerns identified during routine checks. Cipla emphasized its commitment to patient safety and regulatory standards, ensuring corrective measures are underway.  

Impact On Supply  
Industry experts anticipate a short-term shortage of Lanreotide in the US market. Hospitals and pharmacies may face challenges in meeting patient demand until alternative supplies are arranged.  

Company Response  
Cipla has assured that it is working closely with regulators and healthcare providers to minimize disruption. The company is also exploring ways to restore supply quickly while maintaining strict quality standards.  

Key Highlights  

• Cipla US unit recalls Lanreotide injection  
• Temporary supply shortage expected in US market  
• Recall linked to quality and compliance concerns  
• Company assures corrective measures and patient safety focus  
• Healthcare providers may face short-term challenges  

Sources: Reuters, Economic Times, Business Standard